Basilea Pharmaceutica’s H124 results reflect strong momentum across its pipeline and Edison Group expects the pace to accelerate in H224. The key highlight of the period was the FDA approval of Zevtera. Edison now expects all eyes to be on the announcement of a US commercial partner and the Phase III launch for fosmanogepix (expected imminently). Lead product Cresemba continued its outperformance versus Edison’s estimates (16.6% growth in royalties), contributing >90% of H124 revenues of CHF76.3m and driving the company’s FY24 guidance upgrade (group revenues of CHF196m versus CHF183m previously) with H2-weighed milestone payments.
15 August 2024
Comments